Avdoralimab

Names

[ Name ]:
Avdoralimab

Biological Activity

[Description]:

Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> Complement System

Research Areas >> Inflammation/Immunology

[In Vitro]

Avdoralimab (IPH 5401) 选择性阻断人骨髓细胞中的 C5a-C5aR1 相互作用及其下游信号传导。在体外，用 Avdoralimab (10-30 μg/mL) 阻断 C5aR1 可抑制 C5a 诱导的中性粒细胞活化。Avdoralimab 阻断由非常高浓度的 C5a 诱导的嗜中性粒细胞活化。Avdoralimab 还在体外抑制 C5a 诱导的中性粒细胞迁移[1]。

[In Vivo]

在敲入人类 C5aR1 的小鼠（HuC5aR1 KI 小鼠）中，Avdoralimab 阻断嗜中性粒细胞和单核细胞的浸润，阻止白蛋白在支气管肺泡灌洗液 (BALF) 中的释放，并限制 C5a 诱导的急性肺损伤 (ALI) 组织病理学特征[1]。

[References]

[1]. Julien Carvelli, et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature. 2020 Dec;588(7836):146-150.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.